PM-1009

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NamePM-1009
Drug Alias NamePM1009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitorsTransmembrane protein PVRIG antagonists
TargetsT cell immunoglobulin and ITIM domainsTransmembrane protein PVRIG
Therapy Area/IndicationsSolid tumoursLung NeoplasmsLiver Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator Companies +[1]  N/A
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active Companies +[1]  N/A
Inactive CompaniesBaiouentai (Zhuhai) Pharmaceutical Research and Development Co Ltd
Active IndicationsLung NeoplasmsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A